Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix®

Vaccine

Volumn 31, Issue 1, 2012, Pages 165-170

  Kemp, Troy J ^a   Safaeian, Mahboobeh ^b   Hildesheim, Allan ^b   Pan, Yuanji ^a   Penrose, Kerri J ^a   Porras, Carolina ^c   Schiller, John T ^b   Lowy, Douglas R ^b   Herrero, Rolando ^c,d   Pinto, Ligia A ^a  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Antibody; Avidity; Human papillomavirus; Vaccine

Indexed keywords

CROSS REACTING ANTIBODY; NEUTRALIZING ANTIBODY; WART VIRUS VACCINE;

ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; COSTA RICA; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 58; LONG TERM CARE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; VACCINATION; VIRUS LIKE AGENT; WART VIRUS;

ANTIBODIES, NEUTRALIZING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84870542474     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.067     Document Type: Article

References (20)

1. Muñoz N., Manalastas R., Pitisuttithum P., Tresukosol D., Monsonego J., Ault K., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373(June (9679)):1949-1957.
2. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(July (9686)):301-314.
3. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95(December (11)):1459-1466.
4. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369(June (9580)):2161-2170.
5. Kemp T.J., Hildesheim A., Safaeian M., Dauner J.G., Pan Y., Porras C., et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011, 29(March (11)):2011-2014.
6. Bogaards J.A., Coupe V.M., Meijer C.J., Berkhof J. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine 2011, 29(November (48)):8929-8936.
7. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011, 7(December (12)):1359-1373.
8. Hangartner L., Zinkernagel R.M., Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006, 6(March (3)):231-243.
9. Khurana S., Verma N., Yewdell J.W., Hilbert A.K., Castellino F., Lattanzi M., et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011, 3(June (85)):85ra48.
10. Roost H.P., Bachmann M.F., Haag A., Kalinke U., Pliska V., Hengartner H., et al. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc Natl Acad Sci USA 1995, 92(February (5)):1257-1261.
11. Herrero R., Hildesheim A., Rodriguez A.C., Wacholder S., Bratti C., Solomon D., et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008, 26(September (37)):4795-4808.
12. Kemp T.J., Garcia-Pineres A., Falk R.T., Poncelet S., Dessy F., Giannini S.L., et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008, 26(July (29-30)):3608-3616.
13. Safaeian M., Ghosh A., Porras C., Lin S.W., Rodriguez A.C., Schiffman M., et al. Direct comparison of HPV16 serological assays used to define HPV-naive women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev 2012, 21(September (9)):1547-1554.
14. Dauner J.G., Pan Y., Hildesheim A., Kemp T.J., Porras C., Pinto L.A. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes 2012, 26(April (2)):73-80.
15. Pinto L.A., Viscidi R., Harro C.D., Kemp T.J., Garcia-Pineres A.J., Trivett M., et al. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 2006, 353(September (2)):451-462.
16. Smith J.F., Brownlow M., Brown M., Kowalski R., Esser M.T., Ruiz W., et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007, 3(July-August (4)):109-115.
17. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(November (11)):1048-1056.
18. Malagon T., Drolet M., Boily M.C., Franco E.L., Jit M., Brisson J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(October (10)):781-789.
19. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103(October (19)):1444-1451.
20. Siegrist C.A., Pihlgren M., Tougne C., Efler S.M., Morris M.L., AlAdhami M.J., et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 2004, 23(December (5)):615-622.